INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary Progress Report on Cancer Breakthroughs 2020 Project Presented by Dr. Soon-Shiong at J.P. Morgan Healthcare Conference
Complete Responses Noted in Multiple Tumor Types (including Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer, Merkel Cell Cancer, Bladder Cancer, and Non-Hodgkin’s Lymphoma) when Natural Killer cells and T cells are activated simultaneously FDA Registrationfilings in Bladder,
View HTML
Toggle Summary NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15 Fusion Protein
World’s first combination of tumor-targeted, off-the-shelf PD-L1-targeted Natural Killer cells with IL-15 fusion protein (N-803) to induce immune system activation of both the NK and T-cells demonstrated complete response in second-line metastatic pancreatic cancer, confirmed by PET/CT scan.
View HTML
Toggle Summary ImmunityBio to Present at the 38th Annual J.P. Morgan Healthcare Conference
Company Chairman and CEO to Present Clinical Status Report on QUILT Cancer Breakthrough 2020 Trials in Multiple Tumor Types and Data Update on the Company’s N-803 IL-15 Superagonist, which Recently Received Breakthrough Therapy Designation from the FDA    CULVER CITY, Calif., January 7, 2020  – 
View HTML
Toggle Summary NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Natural Killer Cell Combination Immunotherapy With Durable, Complete Response Data and 78% Disease Control in Refractory Triple Negative Breast Cancer at SABCS
World’s first combination of off-the-shelf NK with checkpoint inhibitor plus antigen simulation via adenovirus to induce immune system activation Ongoing durable complete responses ranging from 8 to 11 months observed in TNBC patients who failed standard of care Disease control rate of 78% and
View HTML
Toggle Summary NantKwest Announces Phase 1 Results for First-in-Human PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) in Patients with Locally Advanced or Metastatic Solid Cancers
First-in-human trial shows no dose-limiting toxicities in six subjects treated as out-patients with PD-L1.t-haNK off-the-shelf CAR NK cell therapy with potential to overcome limitations of CAR-T therapies for solid tumors CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 2, 2019-- NantKwest, Inc.
View HTML
Toggle Summary NantKwest Hosting Key Opinion Leader Meeting on Novel Immunotherapeutic Approaches to Address the Unmet Medical Needs of Patients with Merkel Cell Carcinoma, Triple-Negative Breast Cancer and Solid Tumors
CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 27, 2019-- NantKwest, Inc. (Nasdaq: NK), a next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and other diseases, today
View HTML
Toggle Summary NantKwest Announces Presentation of Positive Phase 2 Clinical Data of Natural Killer Cell Therapy in Metastatic Merkel Cell Carcinoma at SITC 2019
Durable Responses Demonstrated in 2 of 7 Patients with Refractory Metastatic MCC Data Supportive of Planned Off-the-Shelf Clinical Trial to Confirm Activity and Safety CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 7, 2019-- NantKwest Inc. (Nasdaq: NK), a next generation, clinical-stage immunotherapy
View HTML
Toggle Summary NantKwest Launches First-in-class, First-in-human Phase I Clinical Trial With a Targeted PD-L1 t-haNK Cell Therapy in Patients With Solid Tumors
First engineered, GMP-grade, cryopreserved, off-the-shelf, bi-specific NK cell therapy to enter human clinical trials targeting PD-L1 and CD16 in patients with solid tumors NantKwest establishes a leading portfolio of off-the-shelf NK cells at clinical stage of development with three engineered
View HTML
Toggle Summary Cheryl Cohen Appointed to NantKwest’s Board of Directors
CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 6, 2019-- NantKwest ( Nasdaq:NK ) today announced the appointment of Cheryl L. Cohen to the Board of Directors of NantKwest , effective immediately. “Cheryl is a proven business executive and highly experienced board member in both the biotechnology and
View HTML
Toggle Summary NantKwest Announces Durable Complete Responses in Multiple Advanced-Stage Solid Tumor Cancers Following Off-the-Shelf NK Cell Therapy in First 35 Patients
5 out of 35 Durable Complete Responses Observed in Patients with Relapsed Third-Line Advanced Solid Tumors with Duration Ranging 4 to 24 Months CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 4, 2019-- Patrick Soon-Shiong , MD, Chairman and CEO of NantKwest (Nasdaq:NK), a leading clinical-stage,
View HTML